Sparstolonin B

Sparstolonin B acts as a selective TLR2 and TLR4 antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti- HIV and anticancer activities In Vitro Sparstolonin B (1-20 µM; 2-4 days) inhibits cell growth and viability of neuroblastoma cells. Sparstolonin B inhibits TLR ligand-induced cytokine expression in mouse macrophages. Sparstolonin B inhibits MyD88 recruitment to TLR4 and TLR2. Sparstolonin B generates reactive oxygen species (ROS) in neuroblastoma cells. Sparstolonin B reduces expression of N-myc in neuroblastoma cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: SH-SY5Y, IMR-32, NGP, SKNF-1 and SK-N-BE(2) cells Concentration: 1 µM, 5 µM, 10 µM or 20 µM Incubation Time: 2-4 days Result: Effectively and dose-dependently inhibits the viability of all neuroblastoma cell lines after 2 days (SH-SY5Y and IMR-32), 3 days (NGP cells) or 4 days (SKNF-1 and SK-N-BE(2) cells) treatment. In Vivo Sparstolonin B (100 μg/mouse; i.p.) suppresses LPS-provoked inflammation in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 5-6-week-old male C57Bl/6 mice (body weight 18-20 g) Dosage: 100 μg/mouse Administration: I.p. Result: Significantly lower TNFα and IL-1β expression levels in LPS-induced sepsis mouse model. Form:Solid IC50& Target:TLR2|TLR4|HIV-1

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet